rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Sol-Gel Technologies Ltd. -

SLGL · Nasdaq

Health CarePharmaceuticalsNot moving yet

SLGL stood above a rising 150-day average in 44 of the last 52 weekly readings, and has been out of that trend for the last 8 weeks. It is 12.4% below that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 8
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$18.9M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
23 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$5.5MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months43
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Opaleye Management Inc.10% ownerbought1,493at $65.9511 Sep 2026filed 14 Sep 2026
Opaleye Management Inc.10% ownerbought1,631at $66.8010 Sep 2026filed 14 Sep 2026
Opaleye Management Inc.10% ownerbought3,097at $68.719 Sep 2026filed 9 Sep 2026
Opaleye Management Inc.10% ownerbought3,390at $68.748 Sep 2026filed 9 Sep 2026
Opaleye Management Inc.10% ownerbought471at $69.378 Sep 2026filed 9 Sep 2026
Opaleye Management Inc.10% ownerbought918at $69.524 Sep 2026filed 9 Sep 2026
Opaleye Management Inc.10% ownerbought2,100at $68.984 Sep 2026filed 9 Sep 2026
Opaleye Management Inc.10% ownerbought900at $68.952 Sep 2026filed 3 Sep 2026
Opaleye Management Inc.10% ownerbought783at $69.521 Sep 2026filed 3 Sep 2026
Opaleye Management Inc.10% ownerbought5,000at $68.2431 Aug 2026filed 31 Aug 2026
Opaleye Management Inc.10% ownerbought217at $69.1031 Aug 2026filed 31 Aug 2026
Opaleye Management Inc.10% ownerbought10,000at $71.4028 Aug 2026filed 31 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders23+3 on the quarter
New · exited5 · 2
Reported value$97.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Opaleye Management Inc.unchanged · filed 14 Aug 2026500,000$37.1M00.0%
GREAT POINT PARTNERS LLCunchanged · filed 14 Aug 2026274,363$20.3M00.0%
Phoenix Financial Ltd.reduced · filed 11 Aug 2026146,147$10.8M-64,702−30.7%
Trails Edge Capital Partners, LPadded · filed 14 Aug 2026139,445$10.3M+53,949+63.1%
Affinity Asset Advisors, LLCadded · filed 13 Aug 202684,900$6.3M+49,900+142.6%
Squadron Capital Management LLCadded · filed 14 Aug 202652,000$3.9M+21,000+67.7%
CITADEL ADVISORS LLCreduced · filed 14 Aug 202632,556$2.4M-4,589−12.4%
GILDER GAGNON HOWE & CO LLCnew · filed 14 Aug 202622,500$1.7M+22,500
Stonepine Capital Management, LLCreduced · filed 14 Aug 202614,469$1.1M-13,309−47.9%
Yelin Lapidot Holdings Management Ltd.reduced · filed 3 Aug 202610,384$770K-7,369−41.5%
31 Mar 2023 – 30 Jun 2026
91622Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Opaleye Management Inc. Company insider10% owner · last 11 Sep 202643 · 0

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-38.9%
Free cash flow marginFY 2025 · to 31 Dec 20251.4%
Return on capital employedFY 2025 · to 31 Dec 2025-31.7%
Research spendFY 2025 · to 31 Dec 2025118%
Revenue growthFY 2025 · to 31 Dec 202568.0%
Share count trendFY 2025 · to 31 Dec 2025-90.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$11.0M
Free cash flowFY 2025 · to 31 Dec 2025$275K

Analyst forecasts

No analyst forecasts yet.